The 99 were randomized to receive injections of placebo prior to progression while the 233 received injections of DCVax-L prior to progression. The 99 lived longer.
That after progression patients could do whatever was the design of the trial. It does not change the core fact that 99 lived longer.
Dr. Liau implied in one of her presentations during the Q+A period that the 29 permanent placebos had an mOS that was most likely lower than that of the placebos.
When the principal investigator has to IMPLY that the mOS was "most likely lower" when she has all the damn data (yet the company won't provide a complete data set) then that's a huge problem.